Brixton Biosciences is a clinical-stage life sciences company that develops therapies for chronic and acute pain.
Brixton Biosciences has raised $2.0M in total funding. The most recent round was Grant. The last funding was announced in October 2024.
Brixton Biosciences's investors include SV Health Investors, National Institutes of Health, Catalyst Health Ventures, Excelestar Ventures, Schooner Capital.
Brixton Biosciences is headquartered in Cambridge, United States.
Brixton Biosciences is a clinical-stage life sciences company that develops therapies for chronic and acute pain.
Brixton Biosciences is at the Grant stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Brixton Biosciences — Funding & Investors." VCBacked, October 25, 2024, https://www.vcbacked.co/company/brixton-biosciences. Accessed July 19, 2026.
VCBacked. (2024). Brixton Biosciences — Funding & Investors. Retrieved July 19, 2026, from https://www.vcbacked.co/company/brixton-biosciences
{{cite web |title=Brixton Biosciences — Funding & Investors |url=https://www.vcbacked.co/company/brixton-biosciences |website=VCBacked |access-date=July 19, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated